RDY Stock - Dr. Reddy's Laboratories Limited
Unlock GoAI Insights for RDY
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $325.54B | $279.16B | $245.88B | $214.39B | $2.56B |
| Gross Profit | $190.43B | $163.61B | $139.34B | $113.84B | $1.30B |
| Gross Margin | 58.5% | 58.6% | 56.7% | 53.1% | 50.8% |
| Operating Income | $71.84B | $67.73B | $57.14B | $29.48B | $431.44M |
| Net Income | $56.54B | $55.68B | $45.07B | $23.57B | $232.21M |
| Net Margin | 17.4% | 19.9% | 18.3% | 11.0% | 9.1% |
| EPS | $67.85 | $66.80 | $54.29 | $28.42 | $20.79 |
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), Proprietary Products, and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations. This segment also engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. Its Proprietary Products segment focuses on the research and development of differentiated formulations. The Others segment engages in developing therapies in the fields of oncology and inflammation. The therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. The company has a collaboration, license, and option agreement with Curis, Inc. to discover, develop, and commercialize small molecule antagonists for immuno-oncology and precision oncology targets. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.
Visit WebsiteEarnings History & Surprises
RDYEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 7, 2026 | — | — | — | — |
Q1 2026 | Jan 22, 2026 | $0.16 | — | — | — |
Q4 2025 | Oct 24, 2025 | $0.18 | $0.19 | +5.6% | ✓ BEAT |
Q3 2025 | Jul 23, 2025 | $0.18 | $0.20 | +11.1% | ✓ BEAT |
Q2 2025 | May 9, 2025 | $0.20 | $0.22 | +10.0% | ✓ BEAT |
Q1 2025 | Jan 29, 2025 | $0.19 | — | — | — |
Q4 2024 | Nov 5, 2024 | $0.04 | $0.04 | -9.8% | ✗ MISS |
Q3 2024 | Jul 27, 2024 | $0.22 | $0.20 | -9.1% | ✗ MISS |
Q2 2024 | Jun 12, 2024 | — | $0.20 | — | — |
Q2 2024 | May 7, 2024 | $0.17 | $0.19 | +11.8% | ✓ BEAT |
Q4 2023 | Oct 27, 2023 | $0.18 | $0.21 | +16.7% | ✓ BEAT |
Q3 2023 | Jul 26, 2023 | $0.14 | $0.21 | +50.0% | ✓ BEAT |
Q2 2023 | Jun 13, 2023 | — | $0.18 | — | — |
Q2 2023 | May 10, 2023 | $0.11 | $0.14 | +27.3% | ✓ BEAT |
Q4 2022 | Oct 28, 2022 | $0.12 | $0.16 | +33.3% | ✓ BEAT |
Q3 2022 | Jul 28, 2022 | $0.12 | $0.18 | +50.0% | ✓ BEAT |
Q2 2022 | May 19, 2022 | $0.86 | $0.11 | -87.3% | ✗ MISS |
Q1 2022 | Jan 28, 2022 | $0.17 | $0.11 | -34.1% | ✗ MISS |
Q4 2021 | Oct 29, 2021 | — | $0.16 | — | — |
Q3 2021 | Jul 27, 2021 | $0.11 | $0.09 | -18.2% | ✗ MISS |
Latest News
Frequently Asked Questions about RDY
What is RDY's current stock price?
What is the analyst price target for RDY?
What sector is Dr. Reddy's Laboratories Limited in?
What is RDY's market cap?
Does RDY pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to RDY for comparison